|
MARCH8 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6269208202857E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.45941070129174E-12 |
| Normal-vs-Stage2 |
2.01209999994845E-07 |
| Normal-vs-Stage3 |
2.0735635430924E-12 |
| Normal-vs-Stage4 |
1.29280031124779E-10 |
| Stage1-vs-Stage2 |
8.879200E-01 |
| Stage1-vs-Stage3 |
1.976030E-01 |
| Stage1-vs-Stage4 |
8.068100E-02 |
| Stage2-vs-Stage3 |
4.395200E-01 |
| Stage2-vs-Stage4 |
2.482000E-01 |
| Stage3-vs-Stage4 |
5.938400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.765254609154E-14 |
| Normal-vs-AfricanAmerican |
3.181900E-04 |
| Normal-vs-Asian |
7.49009965161918E-10 |
| Caucasian-vs-AfricanAmerican |
3.216400E-01 |
| Caucasian-vs-Asian |
4.242000E-01 |
| AfricanAmerican-vs-Asian |
1.353600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.73923114693753E-13 |
| Normal-vs-Female |
1.7466028623403E-12 |
| Male-vs-Female |
2.540400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.06569999888973E-10 |
| Normal-vs-Age(41-60Yrs) |
2.60125254669674E-13 |
| Normal-vs-Age(61-80Yrs) |
1.19340093363007E-11 |
| Normal-vs-Age(81-100Yrs) |
8.445400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.412200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.632000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.226600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.249400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.778600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.626000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.426000E-02 |
| Classical-VS-Follicular |
1.982770E-01 |
| Classical-VS-Other |
1.094420E-01 |
| Classical-VS-Normal |
3.225419931141E-12 |
| Tall-VS-Follicular |
2.832800E-01 |
| Tall-VS-Other |
5.050800E-01 |
| Tall-VS-Normal |
6.68370025991294E-10 |
| Follicular-VS-Other |
2.995800E-01 |
| Follicular-VS-Normal |
7.30860039155345E-10 |
| Other-VS-Normal |
3.386400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.95055083196394E-12 |
| Normal-vs-N1 |
8.46740455529016E-11 |
| N0-vs-N1 |
8.019500E-02 |
|
|
